Sermorelin — Safety, Research, Risks & Legal Status

Not medical advice. Sermorelin is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	GRF 1-29, sermorelin acetate, Geref
Category	Peptide
not_fda_approved_for_human_use	The branded drug Geref was discontinued; current sources are compounding pharmacies or research chemicals
pituitary_dependent	Requires a functional pituitary to work; ineffective in pituitary failure
wada_banned	Prohibited at all times in sport as a GH secretagogue
US legal status	Sermorelin was previously an FDA-approved prescription drug (Geref) used in diagnostics and pediatric growth hormone deficiency, but the branded product was discontinued in the United States around 2008. It is no longer commercially available as an approved drug and is now distributed mainly through compounding pharmacies and as a research chemical. It is prohibited in sport under the WADA list.

What is Sermorelin?

Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of growth-hormone-releasing hormone (GHRH). It acts on the pituitary to stimulate the body's own pulsatile release of growth hormone. Sermorelin works via endogenous mechanisms rather than supplying hormone directly. This indirect approach was historically valued for diagnostics and pediatric populations, as it preserves the body's natural feedback regulation.

How it works

Sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering intracellular signaling cascades that promote growth hormone synthesis and secretion. It mimics the natural pulsatile pattern of endogenous GHRH, which allows the pituitary to maintain its characteristic GH secretory rhythm. This mechanism preserves negative-feedback control via IGF-1 and somatostatin, unlike direct GH administration.

Background & history

Sermorelin was developed as a therapeutic agent in the 1980s and was approved by the FDA as Geref for use in pediatric growth hormone deficiency diagnostics and short-stature management. The branded product was withdrawn from the market around 2008, but compounding pharmacies continue to produce it. Its decline in pharmaceutical use reflects both generic competition and the shift toward recombinant GH and newer GH secretagogues.

What the research says

Research suggests sermorelin can raise endogenous growth hormone and IGF-1 levels by stimulating the pituitary, and it was historically studied as a diagnostic agent and in pediatric growth hormone deficiency. Human evidence for broader anti-aging or body-composition uses is limited and largely dated, and most modern claims rest on small or older studies rather than robust trials. Some reports suggest potential benefits for sleep quality and lean mass, though these remain preliminary and not widely confirmed in recent controlled studies.

Reported effects

Reported increase in endogenous growth hormone secretion
Studied rises in IGF-1 levels
Reported improvements in sleep quality in some users
Studied as a diagnostic probe of pituitary function
Reported effects on body composition in early research
Studied preservation of natural GH pulsatility patterns

Dosing & administration (informational)

In clinical research, sermorelin has been administered by subcutaneous or intramuscular injection in doses ranging from 1 to 2 micrograms per kilogram of body weight, typically given once or twice daily or as diagnostic provocative doses of 1 microgram per kilogram. Studies often examined effects over weeks to months, with growth hormone peaks measured 30 to 60 minutes post-injection.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Injection carries risks of pain, bruising, infection, and injection-site reactions when sterile technique is not followed
Raising growth hormone and IGF-1 can theoretically promote insulin resistance, edema, and joint pain
Elevated GH and IGF-1 are a theoretical concern for anyone with an active or prior cancer, since IGF-1 is a growth signal
Prohibited at all times in sport under the WADA list as a GH secretagogue
Material sold as a research chemical may be impure, mislabeled, or contaminated
May cause carpal tunnel and other compression neuropathies with prolonged elevation of GH and IGF-1

Drug & supplement interactions

Somatostatin and SST analogs antagonize sermorelin's GH-releasing effect
Beta-blockers and other drugs affecting adrenergic tone may blunt GH secretion
Glucocorticoids suppress endogenous GH secretion and can reduce sermorelin efficacy
Concurrent use with other GH secretagogues not well studied and not recommended

Who should avoid it

Active malignancy or personal history of cancer (IGF-1 is a growth signal)
Uncontrolled diabetes or severe glucose dysregulation
Severe sleep apnea (may be exacerbated by GH elevation)
Severe hypothyroidism (thyroid hormone is required for optimal GH action)
Acute critical illness or sepsis

How it is commonly combined

Sermorelin is sometimes combined with GHS-R agonists (e.g., GHRP) or thyrotropin-releasing hormone (TRH) analogs in animal and early human research to achieve synergistic GH release. Such combinations remain experimental and are not standard clinical practice.

Legal & regulatory. Sermorelin was previously an FDA-approved prescription drug (Geref) used in diagnostics and pediatric growth hormone deficiency, but the branded product was discontinued in the United States around 2008. It is no longer commercially available as an approved drug and is now distributed mainly through compounding pharmacies and as a research chemical. It is prohibited in sport under the WADA list.

Quality & harm reduction

P
r
e
f
e
r
s
o
u
r
c
e
s
t
h
a
t
p
r
o
v
i
d
e
a
t
h
i
r
d
-
p
a
r
t
y
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
(
C
O
A
)
w
i
t
h
H
P
L
C
a
n
d
m
a
s
s
s
p
e
c
t
r
o
m
e
t
r
y
d
a
t
a
c
o
n
f
i
r
m
i
n
g
i
d
e
n
t
i
t
y
a
n
d
p
u
r
i
t
y
.
E
n
d
o
t
o
x
i
n
(
L
A
L
)
t
e
s
t
i
n
g
i
s
i
m
p
o
r
t
a
n
t
f
o
r
a
n
y
i
n
j
e
c
t
a
b
l
e
p
e
p
t
i
d
e
.
U
s
e
s
t
e
r
i
l
e
r
e
c
o
n
s
t
i
t
u
t
i
o
n
p
r
a
c
t
i
c
e
s
a
n
d
c
o
l
d
s
t
o
r
a
g
e
a
s
d
i
r
e
c
t
e
d
t
o
p
r
e
s
e
r
v
e
s
t
a
b
i
l
i
t
y
a
n
d
m
i
n
i
m
i
z
e
i
n
f
e
c
t
i
o
n
r
i
s
k
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Is sermorelin the same as taking growth hormone?

No. Sermorelin stimulates the pituitary to release the body's own growth hormone rather than supplying GH directly, so its effect depends on a functioning pituitary.

What dose should I take?

We do not provide human dosing guidance. Dosing decisions belong with a qualified clinician, and many uses are unapproved.

Is sermorelin legal to buy in the US?

The approved branded drug was discontinued, and the peptide is now obtained mainly via compounding pharmacies by prescription or sold as a research chemical not approved for general human use.

Does sermorelin preserve natural GH pulsatility?

Unlike direct GH injections, sermorelin mimics the body's natural pulsatile GHRH signal, which may better preserve the normal GH secretion pattern and feedback loops.

Why is IGF-1 elevation a cancer concern?

IGF-1 is a potent cell-growth and proliferation signal; sustained elevation is theoretically linked to cancer risk, particularly in people with prior or active malignancy.

References & further reading

PubMed: sermorelin growth hormone secretion
PubMed: GHRH analog pediatric growth hormone deficiency
FDA: Geref (sermorelin acetate) prescribing information archive
WADA Prohibited List: GHRH and analogs
ClinicalTrials.gov: sermorelin growth hormone